BioAxone BioSciences, Inc.
Records under this name other than the patents BioAxone BioSciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 14 patents it holds.
Showing 1 to 7 of 7 · Back to BioAxone BioSciences, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,491,692 | Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof Term ended Term ended Feb 28, 2023 · USPTO record | Term ended | Term ended Feb 28, 2023 | USPTO record |
| US 6,855,688 | ADP-ribosyl transferase fusion proteins, pharmaceutical compositions, and methods of use Term ended Term ended Sep 25, 2022 · USPTO record | Term ended | Term ended Sep 25, 2022 | USPTO record |
| US 7,795,218 | ADP-ribosyl transferase fusion variant proteins Formerly held Lapsed on the fee record Ended Sep 14, 2022 · USPTO record | Lapsed on the fee record | Ended Sep 14, 2022 | USPTO record |
| US 7,910,554 | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions Term ended Ended no later than Apr 9, 2022 · USPTO record | Term ended | Ended no later than Apr 9, 2022 | USPTO record |
| US 7,141,428 | Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof Term ended Term ended Nov 8, 2021 · USPTO record | Term ended | Term ended Nov 8, 2021 | USPTO record |
| US 7,442,686 | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions Lapsed on the fee record Ended Oct 28, 2020 · USPTO record | Lapsed on the fee record | Ended Oct 28, 2020 | USPTO record |
| US 7,169,783 | (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion Term ended Term ended Dec 10, 2018 · USPTO record | Term ended | Term ended Dec 10, 2018 | USPTO record |